These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36089471)

  • 1. Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021.
    Lin KY; Hsieh MJ; Chang SY; Ieong SM; Cheng CY; Sheng WH; Chang SC
    J Formos Med Assoc; 2022 Dec; 121(12):2438-2445. PubMed ID: 36089471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
    Kang CM; Lee NY; Lin CH; Hsu YS; Chang YC; Chung MY; Lee YF; Tseng WP; Wu JL; Chen SY; Lu MC; Ko WC; Lee PI; Hsueh PR
    J Clin Virol; 2022 Jun; 150-151():105156. PubMed ID: 35413588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.
    Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
    Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
    Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
    J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
    Kulkarni PS; Gunale B; Kohli S; Lalwani S; Tripathy S; Kar S; Raut S; Kulkarni P; Apte A; Bavdekar A; Bhalla HL; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Pryor M; Hamilton S; Thakar M; Sannidhi RS; Baranwal P; Bhamare C; Dharmadhikari A; Gupta M; Poonawalla CS; Shaligram U; Kapse D;
    Sci Rep; 2023 Oct; 13(1):16579. PubMed ID: 37789040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination.
    Catry E; Favresse J; Gillot C; Bayart JL; Frérotte D; Dumonceaux M; Evrard P; Mullier F; Douxfils J; Carlier FM; Closset M
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological responses to COVID-19 vaccination in patients with chronic liver diseases.
    Huang YS; Hsieh SM; Tsai FC; Tung CC; Yang HC; Chang SY; Wang JT; Liu CJ; Su TH; Kao JH
    J Formos Med Assoc; 2024 Nov; 123(11):1194-1197. PubMed ID: 38906731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval.
    Sheng WH; Chang SY; Hsieh MJ; Ieong SM; Chang SC
    J Formos Med Assoc; 2023 Feb; 122(2):187-191. PubMed ID: 35987747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.
    Kaku CI; Champney ER; Normark J; Garcia M; Johnson CE; Ahlm C; Christ W; Sakharkar M; Ackerman ME; Klingström J; Forsell MNE; Walker LM
    Science; 2022 Mar; 375(6584):1041-1047. PubMed ID: 35143256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
    Rose W; Raju R; Babji S; George A; Madhavan R; Leander Xavier JV; David Chelladurai JS; Nikitha OS; Deborah AA; Vijayakumar S; Immanuel S; John J; Rupali P; Abhilash KPP; Mohan VR; Tallapaka KB; Samuel P; Kang G
    Lancet Reg Health Southeast Asia; 2023 Jan; 12():100141. PubMed ID: 36712811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Nantanee R; Aikphaibul P; Jaru-Ampornpan P; Sodsai P; Himananto O; Theerawit T; Sophonphan J; Tovichayathamrong P; Manothummetha K; Laohasereekul T; Hiransuthikul N; Hirankarn N; Puthanakit T;
    Vaccine; 2022 May; 40(24):3320-3329. PubMed ID: 35513961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study.
    Golec M; Zembala-John J; Fronczek M; Konka A; Bochenek A; Wystyrk K; Botor H; Zalewska M; Chrapiec M; Kasperczyk S; Brzoza Z; Bułdak RJ
    PLoS One; 2023; 18(6):e0287128. PubMed ID: 37310975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients.
    Laham G; Martínez AP; Rojas Gimenez W; Amaya L; Abib A; Echegoyen N; Díaz C; Lucero A; Martelli A; Videla C; Neukam K; Di Lello FA
    J Nephrol; 2023 Apr; 36(3):861-872. PubMed ID: 36152219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report.
    Intapiboon P; Pinpathomrat N; Juthong S; Uea-Areewongsa P; Ongarj J; Siripaitoon B
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.
    Sharifi Aliabadi L; Karami M; Barkhordar M; Hashemi Nazari SS; Kavousi A; Ahmadvand M; Vaezi M
    Front Immunol; 2023; 14():1237916. PubMed ID: 37593732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.